Figure 3: LXR agonists attenuate the expression of the human Pcyt2 gene. (a) The human breast cancer cells MCF-7 were transfected with the human Pcyt2 promoter-luciferase reporter construct and treated with TO901317 (1 μM), 25-OH (10 ng/μL) or 22(R)-OH (10 ng/μL) for 48 hours. Luciferase activities for untreated and treated cells were performed. Shown are means ±S.D. of at least in four independent experiments in duplicate, and significant differences are indicated as (*) at P < .05, (**) at P < .01, and (***) at P < .001. (b) Attenuation of total and α Pcyt2 proteins after various treatments as in (a).